Fragile X Syndrome: Supportive Treatment, Unmet Needs, and Paths to Novel Interventions and Disease-Targeted...

Area of Science:

• Neuroscience
• Genetics
• Developmental Biology

Background:

• Fragile X syndrome (FXS) is a leading monogenic cause of intellectual disability and autism spectrum disorder.
• Molecular and neuronal mechanisms underlying FXS have been identified, suggesting targeted therapeutic approaches.
• Translating basic science and animal model findings into effective human treatments for FXS has proven challenging.

Purpose of the Study:

• To address the difficulties in translating FXS research findings to human clinical applications.
• To outline a coordinated strategy for advancing FXS research and care.
• To foster collaboration among researchers, clinicians, and families to accelerate progress in FXS.

Main Methods:

• Organizing the FXS research field through interlocking projects.
• Developing initiatives for improved supportive care and accessible clinical research.
• Establishing collaborative research on natural history and outcome measures.
• Creating clinical trial consortia and novel trial designs.

Main Results:

• The FXS field has unified to create a structured approach to research and clinical translation.
• Enhanced supportive care and accessible research are being prioritized.
• Collaborative efforts are underway for natural history studies and outcome measure development.
• New clinical trial consortia and innovative trial designs are being implemented.

Conclusions:

• A coordinated, collaborative approach is essential to overcome challenges in FXS research and treatment.
• These organized initiatives aim to improve the lives of individuals with FXS.
• The strategic organization of the FXS field is paving the way for future therapeutic advancements.